CD20-directed Cytolytic Antibody [EPC] - N0000175657

  1. Home
  2. Pharmacologic Class Index
  3. CD20-directed Cytolytic Antibody [EPC] - N0000175657

Pharmacologic Class Information

Pharmacologic Code N0000175657
Pharmacologic Name CD20-directed Cytolytic Antibody
Pharmacologic Uses
  • CD20-directed cytolytic antibody
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with CD20-directed Cytolytic Antibody

The following table contains 15 products whose active ingredient are classified under the same pharmacologic class CD20-directed Cytolytic Antibody [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
0069-0238Ruxience Non-Proprietary Name: Rituximab-pvvrInjection, SolutionIntravenousPfizer Laboratories Div Pfizer IncACTIVE
0069-0249Ruxience Non-Proprietary Name: Rituximab-pvvrInjection, SolutionIntravenousPfizer Laboratories Div Pfizer IncACTIVE
0078-0669Arzerra Non-Proprietary Name: OfatumumabInjection, SolutionIntravenousNovartis Pharmaceuticals CorporationACTIVE
0078-0690Arzerra Non-Proprietary Name: OfatumumabInjection, SolutionIntravenousNovartis Pharmaceuticals CorporationACTIVE
0078-1007Kesimpta Non-Proprietary Name: OfatumumabInjection, SolutionSubcutaneousNovartis Pharmaceuticals CorporationACTIVE
50242-051Rituxan Non-Proprietary Name: RituximabInjection, SolutionIntravenousGenentech, Inc.ACTIVE
50242-053Rituxan Non-Proprietary Name: RituximabInjection, SolutionIntravenousGenentech, Inc.ACTIVE
50242-070Gazyva Non-Proprietary Name: ObinutuzumabInjection, Solution, ConcentrateIntravenousGenentech, Inc.ACTIVE
50242-108Rituxan Hycela Non-Proprietary Name: Rituximab And HyaluronidaseInjection, SolutionSubcutaneousGenentech, Inc.ACTIVE
50242-109Rituxan Hycela Non-Proprietary Name: Rituximab And HyaluronidaseInjection, SolutionSubcutaneousGenentech, Inc.ACTIVE
50242-150Ocrevus Non-Proprietary Name: OcrelizumabInjectionIntravenousGenentech, Inc.ACTIVE
55513-224Riabni Non-Proprietary Name: Rituximab-arrxInjection, SolutionIntravenousAmgen IncACTIVE
55513-326Riabni Non-Proprietary Name: Rituximab-arrxInjection, SolutionIntravenousAmgen IncACTIVE
63459-103Truxima Non-Proprietary Name: Rituximab-abbsInjection, SolutionIntravenousCephalon, Inc.ACTIVE
63459-104Truxima Non-Proprietary Name: Rituximab-abbsInjection, SolutionIntravenousCephalon, Inc.ACTIVE